Is Angioplasty at Centers Without Surgical Backup Safe?

Performing coronary angioplasties at hospitals without surgical backup seems to be safe for a wide variety of patients, from those presenting ST-segment elevation myocardial infarction to those undergoing elective procedures.

 

This work responds to a long-running debate over whether centers without on-site surgery capabilities in case of complications can be considered as referral centers for primary angioplasty (emergency angioplasty) only, or can also perform scheduled procedures.

 

Centers without surgical capabilities have argued in their defense that the performance of scheduled procedures ensured that proper proficiency be maintained for emergency cases.

 

This is the first real-world study showing that it is probably safe to perform coronary angioplasties at centers without surgical backup.

 

The study included data from the Nationwide Inpatient Sample of almost 7 million patients who received an angioplasty in the United States between 2003 and 2012. Overall, 5.7% of the procedures were performed at centers without surgical backup, and the proportion increased with time (1.8% in 2003 vs. 12.7% in 2013; p < 0.001).

 

Hospitals lacking surgical backup performed primary angioplasties more frequently than larger centers with surgical capabilities (34% vs. 20%; p < 0.001).

  • The rate for non-ST-segment elevation acute coronary syndrome was similar (41.8% vs. 42.6%).
  • Scheduled angioplasties were more frequent at centers with surgical capabilities (24.1% vs. 38.2%).
  • Mortality was lower at centers with on-site surgery (1.4% vs. 1.9%; odds ratio [OR] 0.74), but the difference disappeared after researchers adjusted for procedural indication (elective or emergency procedure).

 

The annual angioplasty volume was less than 200 annual cases in two-thirds of the centers without surgical backup.

 

Original title: Outcomes and Temporal Trends of Inpatient Percutaneous Coronary Intervention at Centers With and Without On-site Cardiac Surgery in the United States.

Presenter:  Goel K.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...